Context Therapeutics (NASDAQ:CNTX) Issues Quarterly Earnings Results

Context Therapeutics (NASDAQ:CNTX) issued its earnings results on Thursday. The company reported ($0.04) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.05) by $0.01, reports.

Context Therapeutics Trading Up 0.2 %

CNTX opened at $0.77 on Friday. The business’s 50 day moving average is $0.85 and its 200-day moving average is $1.44. The stock has a market cap of $57.88 million, a PE ratio of -0.85 and a beta of 2.06. Context Therapeutics has a twelve month low of $0.64 and a twelve month high of $2.75.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on CNTX. Citizens Jmp raised shares of Context Therapeutics to a “strong-buy” rating in a research report on Wednesday, January 8th. D. Boral Capital reaffirmed a “buy” rating and set a $9.00 target price on shares of Context Therapeutics in a report on Friday. JMP Securities assumed coverage on Context Therapeutics in a research report on Wednesday, January 8th. They set an “outperform” rating and a $4.00 price target on the stock. Finally, HC Wainwright restated a “buy” rating and set a $5.00 price objective on shares of Context Therapeutics in a research report on Friday. Six analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $6.17.

About Context Therapeutics

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.